Literature DB >> 33678235

A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer.

Nicole G Campos1, Maria Demarco2, Laia Bruni3, Kanan T Desai2, Julia C Gage2, Sally N Adebamowo4, Silvia de Sanjose2, Jane J Kim5, Mark Schiffman2.   

Abstract

Health decision models are the only available tools designed to consider the lifetime natural history of human papillomavirus (HPV) infection and pathogenesis of cervical cancer, and the estimated long-term impact of preventive interventions. Yet health decision modeling results are often considered a lesser form of scientific evidence due to the inherent needs to rely on imperfect data and make numerous assumptions and extrapolations regarding complex processes. We propose a new health decision modeling framework that de-emphasizes cytologic-colposcopic-histologic diagnoses due to their subjectivity and lack of reproducibility, relying instead on HPV type and duration of infection as the major determinants of subsequent transition probabilities. We posit that the new model health states (normal, carcinogenic HPV infection, precancer, cancer) and corollary transitions are universal, but that the probabilities of transitioning between states may vary by population. Evidence for this variability in host response to HPV infections can be inferred from HPV prevalence patterns in different regions across the lifespan, and might be linked to different average population levels of immunologic control of HPV infections. By prioritizing direct estimation of model transition probabilities from longitudinal data (and limiting reliance on model-fitting techniques that may propagate error when applied to multiple transitions), we aim to reduce the number of assumptions for greater transparency and reliability. We propose this new microsimulation model for critique and discussion, hoping to contribute to models that maximally inform efficient strategies towards global cervical cancer elimination.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer screening; Decision analysis; HPV DNA tests; Human papillomavirus (HPV); Mathematical model; Uterine cervical neoplasms

Mesh:

Substances:

Year:  2021        PMID: 33678235      PMCID: PMC8041229          DOI: 10.1016/j.ypmed.2021.106438

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  66 in total

1.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study.

Authors:  M H Stoler; M Schiffman
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

Review 2.  Chapter 19: Cost-effectiveness of cervical cancer screening.

Authors:  Sue J Goldie; Jane J Kim; Evan Myers
Journal:  Vaccine       Date:  2006-06-22       Impact factor: 3.641

3.  Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

Authors:  Daniel C Beachler; Aimée R Kreimer; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Ana Cecilia Rodriguez; Douglas R Lowy; Carolina Porras; John T Schiller; Wim Quint; Silvia Jimenez; Mahboobeh Safaeian; Linda Struijk; John Schussler; Allan Hildesheim; Paula Gonzalez
Journal:  J Natl Cancer Inst       Date:  2015-10-14       Impact factor: 13.506

4.  Time since first sexual intercourse and the risk of cervical cancer.

Authors:  Martyn Plummer; Julian Peto; Silvia Franceschi
Journal:  Int J Cancer       Date:  2011-08-12       Impact factor: 7.396

5.  Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer.

Authors:  Peng Guan; Rebecca Howell-Jones; Ni Li; Laia Bruni; Silvia de Sanjosé; Silvia Franceschi; Gary M Clifford
Journal:  Int J Cancer       Date:  2012-03-20       Impact factor: 7.396

6.  A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion.

Authors:  Martyn Plummer; Mark Schiffman; Philip E Castle; Delphine Maucort-Boulch; Cosette M Wheeler
Journal:  J Infect Dis       Date:  2007-04-16       Impact factor: 5.226

7.  Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,.

Authors:  M Concepción Bratti; Ana C Rodríguez; Mark Schiffman; Allan Hildesheim; Jorge Morales; Mario Alfaro; Diego Guillén; Martha Hutchinson; Mark E Sherman; Claire Eklund; John Schussler; Julie Buckland; Lidia A Morera; Fernando Cárdenas; Manuel Barrantes; Elmer Pérez; Thomas J Cox; Robert D Burk; Rolando Herrero
Journal:  Rev Panam Salud Publica       Date:  2004-02

Review 8.  Modeling preventative strategies against human papillomavirus-related disease in developed countries.

Authors:  Karen Canfell; Harrell Chesson; Shalini L Kulasingam; Johannes Berkhof; Mireia Diaz; Jane J Kim
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

9.  Developing WHO guidelines: Time to formally include evidence from mathematical modelling studies.

Authors:  Matthias Egger; Leigh Johnson; Christian Althaus; Anna Schöni; Georgia Salanti; Nicola Low; Susan L Norris
Journal:  F1000Res       Date:  2017-08-29

10.  Rates of New Human Papillomavirus Detection and Loss of Detection in Middle-aged Women by Recent and Past Sexual Behavior.

Authors:  Proma Paul; Anne Hammer; Anne F Rositch; Anne E Burke; Raphael P Viscidi; Michelle I Silver; Nicole Campos; Ada O Youk; Patti E Gravitt
Journal:  J Infect Dis       Date:  2021-04-23       Impact factor: 5.226

View more
  6 in total

1.  Multistate models for the natural history of cancer progression.

Authors:  Li C Cheung; Paul S Albert; Shrutikona Das; Richard J Cook
Journal:  Br J Cancer       Date:  2022-07-11       Impact factor: 9.075

2.  Different human papillomavirus types share early natural history transitions in immunocompetent women.

Authors:  Sally N Adebamowo; Brian Befano; Li C Cheung; Ana Cecilia Rodriguez; Maria Demarco; Greg Rydzak; Xiaojian Chen; Carolina Porras; Rolando Herrero; Jane J Kim; Philip E Castle; Nicolas Wentzensen; Aimée R Kreimer; Mark Schiffman; Nicole G Campos
Journal:  Int J Cancer       Date:  2022-06-17       Impact factor: 7.316

3.  Reducing Poverty-Related Disparities in Cervical Cancer: The Role of HPV Vaccination.

Authors:  Jennifer C Spencer; Noel T Brewer; Tamera Coyne-Beasley; Justin G Trogdon; Morris Weinberger; Stephanie B Wheeler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-09-09       Impact factor: 4.254

4.  The development of "automated visual evaluation" for cervical cancer screening: The promise and challenges in adapting deep-learning for clinical testing: Interdisciplinary principles of automated visual evaluation in cervical screening.

Authors:  Kanan T Desai; Brian Befano; Zhiyun Xue; Helen Kelly; Nicole G Campos; Didem Egemen; Julia C Gage; Ana-Cecilia Rodriguez; Vikrant Sahasrabuddhe; David Levitz; Paul Pearlman; Jose Jeronimo; Sameer Antani; Mark Schiffman; Silvia de Sanjosé
Journal:  Int J Cancer       Date:  2021-12-06       Impact factor: 7.316

5.  Prevalence and genotype specific concordance of oro-genital and anal human papillomavirus infections among sexually active Nigerian women.

Authors:  Imran O Morhason-Bello; Kathy Baisley; Miquel Angel Pavon; Isaac F Adewole; Rasheed Bakare; Silvia de Sanjosé; Suzanna C Francis; Deborah Watson-Jones
Journal:  Infect Agent Cancer       Date:  2021-09-08       Impact factor: 2.965

6.  The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support.

Authors:  Adam Keane; Chiu Wan Ng; Kate T Simms; Diep Nguyen; Yin Ling Woo; Marion Saville; Karen Canfell
Journal:  Int J Cancer       Date:  2021-08-25       Impact factor: 7.316

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.